Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964802 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL30645650 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL21262219 | 0.79 | L3MBTL1 (0.48) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL30456319 | 0.77 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HPGDHTTNPC1 | |
| SCHEMBL21246720 | 0.75 | KCNQ3 (0.37) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL21409463 | 0.75 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| Acetic Acid SCHEMBL28092089 | 0.74 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HPGDHTTNPC1 | |
| SCHEMBL21262226 | 0.74 | ATR (0.44) | — | |
| SCHEMBL23330674 | 0.73 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL12748231 | 0.73 | KMT2A (0.71) | ALDH1A1SMN1; SMN2LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | ALDH1A1 3717/4885SMN1; SMN2 1936/4885LMNA 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.